About BetaCure

Hyperinsulinemic hypoglycemia is a potentially lethal disease caused by excessive production of insulin by the beta cells of the pancreatic islets of Langerhans. Lethal hypoglycemia and brain damage is a problem especially in infants born with the disease. The major problem of current therapeutic approaches are the frequently observed severe side effects/morbidity.

Objectives

In order to significantly reduce the side effects of current therapeutic approaches and to increase quality of life and life expectancy, BetaCure aims to develop an integrated simultaneous imaging/therapeutic (“theranostic”) platform that will allow diagnostic imaging, targeted image guided surgical, photodynamic and radiopeptide therapy to selectively resect or destroy diseased beta cells.

CHI and AHH

The theranostic platform shall optimize treatment of newborns and infants suffering from congenital hyperinsulinism (CHI) and shall improve the treatment of adult hyperinsulinemic hypoglycemia (AHH) caused by insulin-producing tumours or adult beta cell hyperplasia.

 

Print

Events 2018

31 May 2018

Final Summary Report ready for you to read! 

31 March 2018

The BetaCure project has ended successfully

All events

 

Top
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Until you give your consent, only those cookies necessary to maintain the website's functionality are active. When you choose "OK", so called third-party non-functional cookies (e.g. GDPR-conform Google Analytics) may also become active. Please be aware that the website's functionality may be restricted if you choose "DECLINE". You can revoke your choice at any time by clearing your browser cache/history and updating your selection. Please also view our privacy policy.
Ok Decline